Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study

Osamu Ishimoto, Shunichi Sugawara, Akira Inoue, Makoto Maemondo, Toshihiro Nukiwa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We conducted a phase I dose escalation study to evaluate the feasibility, maximum tolerated dose (MTD), and recommended dose (RD) of weekly irinotecan combined with fixed-dose carboplatin for patients with untreated small-cell lung cancer (SCLC). Methods: Fifteen patients with chemotherapy-naïve SCLC less than 75 years old were enrolled from 3 institutions. Patients received irinotecan (50-80mg/m2 on days 1 and 8) and carboplatin (area under the curve, 5.0 on day 1) every 3 weeks, with 3-6 patients treated at each irinotecan dosage level (levels I-IV). The MTD was defined as the dose at which 33% of patients experienced dose-limiting toxicity. Results: Eleven patients had a performance status of 1, and 7 patients were more than 70 years old. All but 1 patient were diagnosed with extensive disease. In total, 2 of 3 patients enrolled at level IV (80mg/m2) experienced grade 3 diarrhea. Therefore, the MTD was defined as the level IV dose, and the RD was defined as the level III dose (70mg/m2). Grade 3 or 4 neutropenia was observed in 60% of patients, and febrile neutropenia was observed in 13% of patients. Four patients experienced grade 3 or 4 anemia, and 6 patients experienced grade 3 or 4 thrombocytopenia. The most common non-hematological adverse events were nausea/vomiting, diarrhea, hypokalemia, and hyponatremia. Conclusions: The MTD of weekly irinotecan was 80mg/m2, resulting in an RD of 70mg/m2 for phase II trials.

Original languageEnglish
Pages (from-to)156-160
Number of pages5
JournalRespiratory Investigation
Volume53
Issue number4
DOIs
Publication statusPublished - 2015 Jul 1

Keywords

  • Carboplatin
  • Chemotherapy
  • Irinotecan
  • Phase I study
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study'. Together they form a unique fingerprint.

  • Cite this